1. Home
  2. GRBK vs NUVB Comparison

GRBK vs NUVB Comparison

Compare GRBK & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Green Brick Partners Inc.

GRBK

Green Brick Partners Inc.

HOLD

Current Price

$66.68

Market Cap

2.9B

ML Signal

HOLD

NUVB

Nuvation Bio Inc.

HOLD

Current Price

$8.52

Market Cap

2.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GRBK
NUVB
Founded
N/A
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Homebuilding
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.9B
2.9B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
GRBK
NUVB
Price
$66.68
$8.52
Analyst Decision
Buy
Strong Buy
Analyst Count
2
8
Target Price
$71.00
$10.63
AVG Volume (30 Days)
240.4K
10.3M
Earning Date
10-29-2025
11-03-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
7.63
N/A
Revenue
$2,113,173,000.00
$26,748,000.00
Revenue This Year
N/A
$609.55
Revenue Next Year
$0.98
$197.91
P/E Ratio
$8.78
N/A
Revenue Growth
6.62
1137.19
52 Week Low
$50.57
$1.54
52 Week High
$77.93
$8.95

Technical Indicators

Market Signals
Indicator
GRBK
NUVB
Relative Strength Index (RSI) 54.09 68.86
Support Level $63.63 $7.80
Resistance Level $68.19 $8.95
Average True Range (ATR) 1.81 0.51
MACD 0.18 -0.04
Stochastic Oscillator 59.96 77.09

Price Performance

Historical Comparison
GRBK
NUVB

About GRBK Green Brick Partners Inc.

Green Brick Partners Inc is a homebuilding and land development company. It acquires and develops land, as well as provides land and construction financing to its controlled builders. The company has three reportable segments: builder operations central, builder operations southeast, and land development. The majority of the company's revenue is generated from the builder operations central segment which is entirely the operations of builders in Texas. The company is engaged in various aspects of the homebuilding process, including land acquisition and development, entitlements, design, construction, marketing, sales, and brand image creation. In addition to homebuilding, the company provides home financing services, such as mortgage and title.

About NUVB Nuvation Bio Inc.

Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.

Share on Social Networks: